Skip to Main Content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.

The Faculty of Medicine - Immunology and Cancer Research: Ben-Neriah Yinon


Last updated December 2021 -  Immunology and Cancer Research

List of Publications

(1) Venkatachalam A, Pikarsky E, Ben-Neriah Y. Putative homeostatic role of cancer driver mutations. Trends Cell Biol 2022;32(1):8-17.

(2) Fink A, Hung E, Singh I, Ben-Neriah Y. Immunity in acute myeloid leukemia: Where the immune response and targeted therapy meet. Eur J Immunol 2021.

(3) Kadosh E, Snir-Alkalay I, Venkatachalam A, May S, Lasry A, Elyada E, et al. The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic. Nature 2020;586(7827):133-138.

(4) Cohen M, Amir S, Golan M, Ben-Neriah Y, Mabjeesh NJ. β-TrCP upregulates HIF-1 in prostate cancer cells. Prostate 2019;79(4):403-413.

(5) Minzel W, Venkatachalam A, Fink A, Hung E, Brachya G, Burstain I, et al. Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models. Cell 2018;175(1):171-185.e25.

(6) Morgenstern Y, Das Adhikari U, Ayyash M, Elyada E, Tóth B, Moor A, et al. Casein kinase 1-epsilon or 1-delta required for Wnt-mediated intestinal stem cell maintenance. EMBO J 2017;36(20):3046-3061.

(7) Chang C-, Kuo C-, Ito T, Su Y-, Jiang S-, Chiu M-, et al. CK1α ablation in keratinocytes induces p53-dependent, sunburn-protective skin hyperpigmentation. Proc Natl Acad Sci U S A 2017;114(38):E8035-E8044.

(8) Lasry A, Aran D, Butte AJ, Ben-Neriah Y. Cancer cell–autonomous parainflammation mimics immune cell infiltration. Cancer Res 2017;77(14):3740-3744.

(9) Drayman N, Ben-nun-Shaul O, Butin-Israeli V, Srivastava R, Rubinstein AM, Mock CS, et al. P53 elevation in human cells halt SV40 infection by inhibiting T-ag expression. Oncotarget 2016;7(33):52643-52660.

(10) Aran D, Lasry A, Zinger A, Biton M, Pikarsky E, Hellman A, et al. Widespread parainflammation in human cancer. Genome Biol 2016;17(1).

(11) Katlinskaya YV, Katlinski KV, Lasri A, Li N, Beiting DP, Durham AC, et al. Type I interferons control proliferation and function of the intestinal epithelium. Mol Cell Biol 2016;36(7):1124-1135.

(12) Lasry A, Zinger A, Ben-Neriah Y. Inflammatory networks underlying colorectal cancer. Nat Immunol 2016;17(3):230-240.

(13) Finkin S, Yuan D, Stein I, Taniguchi K, Weber A, Unger K, et al. Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. Nat Immunol 2015;16(12):1235-1244.

(14) Ben-Neriah Y. One more wheel for a processing machine. Cell Death Differ 2015;22(8):1235-1236.

(15) Mudduluru G, Abba M, Batliner J, Patil N, Scharp M, Lunavat TR, et al. A systematic approach to defining the microrna landscape in metastasis. Cancer Res 2015;75(15):3010-3019.

(16) Pribluda A, Elyada E, Wiener Z, Hamza H, Goldstein RE, Biton M, et al. Erratum to A Senescence-Inflammatory Switch from Cancer-Inhibitory to Cancer-Promoting Mechanism [Cancer Cell 24, (2013) 242-256]. Cancer Cell 2015;27(6):877-878.

(17) Lasry A, Ben-Neriah Y. Senescence-associated inflammatory responses: Aging and cancer perspectives. Trends Immunol 2015;36(4):217-228.

(18) Horwitz E, Stein I, Ben-Neriah Y, Pikarsky E. Animal model studies indicate a candidate biomarker for sorafenib treatment of hepatocellular carcinoma. Mol Cell Oncol 2015;2(1).

(19) Hefetz-Sela S, Stein I, Klieger Y, Porat R, Sade-Feldman M, Zreik F, et al. Acquisition of an immunosuppressive protumorigenic macrophage phenotype depending on c-Jun phosphorylation. Proc Natl Acad Sci U S A 2014;111(49):17582-17587.

(20) Wiener Z, Högström J, Hyvönen V, Band AM, Kallio P, Holopainen T, et al. Prox1 promotes expansion of the colorectal cancer stem cell population to fuel tumor growth and ischemia resistance. Cell Rep 2014;8(6):1943-1956.

(21) Wiener Z, Band AM, Kallio P, Högström J, Hyvönen V, Kaijalainen S, et al. Oncogenic mutations in intestinal adenomas regulate Bim-mediated apoptosis induced by TGF-β. Proc Natl Acad Sci U S A 2014;111(21):E2229-E2236.

(22) Kanarek N, Grivennikov SI, Leshets M, Lasry A, Alkalay I, Horwitz E, et al. Critical role for IL-1β in DNA damageinduced mucositis. Proc Natl Acad Sci U S A 2014;111(6):E702-E711.

(23) Wiener Z, Högström J, Hyvönen V, Band A, Kallio P, Holopainen T, et al. [Prox1 promotes expansion of the colorectal cancer stem cell population to fuel tumor growth and ischemia resistance]. Duodecim 2014;130(21):2208.

(24) Horwitz E, Stein I, Andreozzi M, Nemeth J, Shoham A, Pappo O, et al. Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to Sorafenib treatment. Cancer Discov 2014;4(6):730-743.

(25) Pribluda A, Elyada E, Wiener Z, Hamza H, Goldstein R, Biton M, et al. A Senescence-inflammatory switch from cancer-inhibitory to cancer-promoting mechanism. Cancer Cell 2013;24(2):242-256.

(26) Perets R, Kaplan T, Stein I, Hidas G, Tayeb S, Avraham E, et al. Genome-Wide Analysis of Androgen Receptor Targets Reveals COUP-TF1 as a Novel Player in Human Prostate Cancer. PLoS ONE 2012;7(10).

(27) Kanarek N, Ben-Neriah Y. Regulation of NF-κB by ubiquitination and degradation of the IκBs. Immunol Rev 2012;246(1):77-94.

(28) Duan S, Skaar J, Kuchay S, Toschi A, Kanarek N, Ben-Neriah Y, et al. MTOR generates an auto-amplification loop by triggering the βTrCP- and CK1α-dependent degradation of DEPTOR. Mol Cell 2011;44(2):317-324.

(29) Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol 2011;12(8):715-723.

(30) Biton M, Levin A, Slyper M, Alkalay I, Horwitz E, Mor H, et al. Epithelial microRNAs regulate gut mucosal immunity via epithelium-T cell crosstalk. Nat Immunol 2011;12(3):239-246.

(31) Elyada E, Pribluda A, Goldstein RE, Morgenstern Y, Brachya G, Cojocaru G, et al. CKIα ablation highlights a critical role for p53 in invasiveness control. Nature 2011;470(7334):409-413.

(32) Baruch K, Gur-Arie L, Nadler C, Koby S, Yerushalmi G, Ben-Neriah Y, et al. Metalloprotease type III effectors that specifically cleave JNK and NF-κB. EMBO J 2011;30(1):221-231.

(33) Amarilyo G, Verbovetski I, Atallah M, Grau A, Wiser G, Gil O, et al. iC3b-opsonized apoptotic cells mediate a distinct anti-inflammatory response and transcriptional NF-κB-dependent blockade. Eur J Immunol 2010;40(3):699-709.

(34) Kanarek N, Horwitz E, Mayan I, Leshets M, Cojocaru G, Davis M, et al. Spermatogenesis rescue in a mouse deficient for the ubiquitin ligase SCFβ-TrCP by single substrate depletion. Genes Dev 2010;24(5):470-477.

(35) Gluschnaider U, Hidas G, Cojocaru G, Yutkin V, Ben-Neriah Y, Pikarsky E. β-TrCP inhibition reduces prostate cancer cell growth via upregulation of the aryl hydrocarbon receptor. PLoS ONE 2010;5(2).

(36) Kanarek N, London N, Schueler-Furman O, Ben-Neriah Y. Ubiquitination and degradation of the inhibitors of NF-kappaB. Cold Spring Harb Perspect Biol 2010;2(2).

(37) Nadler C, Baruch K, Kobi S, Mills E, Haviv G, Farago M, et al. The type III secretion effector NleE inhibits NF-κB activation. PLoS Pathog 2010;6(1).

(38) Németh J, Stein I, Haag D, Riehl A, Longerich T, Horwitz E, et al. S100A8 and S100A9 are novel nuclear factor kappa b target genes during malignant progression of murine and human liver carcinogenesis. Hepatology 2009;50(4):1251-1262.

(39) Qvit N, Hatzubai A, Shalev DE, Ben-Neriah Y, Gilon C. Design and synthesis of backbone cyclic phosphopeptides: The iκb model. Adv Exp Med Biol 2009;611:139-140.

(40) Qvit N, Hatzubai A, Shalev DE, Friedler A, Ben-Neriah Y, Gilon C. Design and synthesis of backbone cyclic phosphorylated peptides: The IκB model. Biopolymers 2009;91(2):157-168.

(41) Vainer GW, Pikarsky E, Ben-Neriah Y. Contradictory functions of NF-κB in liver physiology and cancer. Cancer Lett 2008;267(2):182-188.

(42) Moussaieff A, Shein NA, Tsenter J, Grigoriadis S, Simeonidou C, Alexandrovich AG, et al. Incensole acetate: A novel neuroprotective agent isolated from Boswellia carterii. J Cereb Blood Flow Metab 2008;28(7):1341-1352.

(43) Moussaieff A, Shohami E, Kashman Y, Fride E, Schmitz ML, Renner F, et al. Incensole acetate, a novel anti-inflammatory compound isolated from Boswellia resin, inhibits nuclear factor-κB activation. Mol Pharmacol 2007;72(6):1657-1664.

(44) Weiss YG, Bromberg Z, Raj N, Raphael J, Goloubinoff P, Ben-Neriah Y, et al. Enhanced heat shock protein 70 expression alters proteasomal degradation of IκB kinase in experimental acute respiratory distress syndrome. Crit Care Med 2007;35(9):2128-2138.

(45) Ben-Neriah Y, Schmidt-Supprian M. Epithelial NF-κB maintains host gut microflora homeostasis. Nat Immunol 2007;8(5):479-481.

(46) Lee J, Mo J-, Katakura K, Alkalay I, Rucker AN, Liu Y-, et al. Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells. Nature Cell Biol 2006;8(12):1327-1336.

(47) Pikarsky E, Ben-Neriah Y. NF-κB inhibition: A double-edged sword in cancer? Eur J Cancer 2006;42(6):779-784.

(48) Eldor R, Yeffet A, Baum K, Doviner V, Amar D, Ben-Neriah Y, et al. Conditional and specific NF-κB blockade protects pancreatic beta cells from diabetogenic agents. Proc Natl Acad Sci U S A 2006;103(13):5072-5077.

(49) Ley SC, Ben-Neriah Y. Control of NF-кB activity by ubiquitination. Handbook of Transcription Factor NF-kappaB; 2006. p. 53-85.

(50) Calzado MA, Lüdi KS, Fiebich B, Ben-Neriah Y, Bacher S, Munoz E, et al. Inhibition of NF-κB activation and expression of inflammatory mediators by polyacetylene spiroketals from Plagius flosculosus. Biochim Biophys Acta Gene Struct Expr 2005;1729(2):88-93.

(51) Nickoloff BJ, Ben-Neriah Y, Pikarsky E. Inflammation and cancer: Is the link as simple as we think? J Invest Dermatol 2005;124(6):x-xiv.

(52) Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 2004;431(7007):461-466.

(53) Ben-Neriah Y, Schmitz ML. Of mice and men. Meeting on the biology and pathology of NF-κB. EMBO Rep 2004;5(7):668-673.

(54) Davis M, Ben-Neriah Y. Behind the scenes of anergy: A tale of three E3s. Nat Immunol 2004;5(3):238-240.

(55) Ben-Neriah Y. Pinning NF-κB to the Nucleus. Mol Cell 2003;12(6):1344-1345.

(56) Amit S, Ben-Neriah Y. NF-κB activation in cancer: A challenge for ubiquitination- and proteasome-based therapeutic approach. Semin Cancer Biol 2003;13(1):15-28.

(57) Lavon I, Pikarsky E, Gutkovich E, Goldberg I, Bar J, Oren M, et al. Nuclear factor-κB protects the liver against genotoxic stress and functions independently of p53. Cancer Res 2003;63(1):25-30.

(58) Lang V, Janzen J, Fischer GZ, Soneji Y, Beinke S, Salmeron A, et al. βTrCP-mediated proteolysis of NF-κB1 p105 requires phosphorylation of p105 serines 927 and 932. Mol Cell Biol 2003;23(1):402-413.

(59) Amit S, Hatzubai A, Birman Y, Andersen JS, Ben-Shushan E, Mann M, et al. Axin-mediated CKI phosphorylation of β-catenin at Ser 45: A molecular switch for the Wnt pathway. Genes Dev 2002;16(9):1066-1076.

(60) Amit S, Ben-Neriah Y. NFκB: Bench to Bedside - Keystone Symposium: 25 February - 3 March 2002, Keystone, CO, USA. IDrugs 2002;5(4):331-335.

(61) Davis M, Hatzubai A, Andersen JS, Ben-Shushan E, Fisher GZ, Yaron A, et al. Pseudosubstrate regulation of the SCFβ-TrCP ubiquitin ligase by hnRNP-U. Genes Dev 2002;16(4):439-451.

(62) Ben-Neriah Y. Regulatory functions of ubiquitination in the immune system. Nat Immunol 2002;3(1):20-26.

(63) Vogt Sionov R, Coen S, Goldberg Z, Berger M, Bercovich B, Ben-Neriah Y, et al. c-Abl regulates p53 levels under normal and stress conditions by preventing its nuclear export and ubiquitination. Mol Cell Biol 2001;21(17):5869-5878.

(64) Shteper PJ, Siegfried Z, Asimakopoulos FA, Palumbo GA, Rachmilewitz EA, Ben-Neriah Y, et al. ABL1 methylation in Ph-positive ALL is exclusively associated with the P210 form of BCR-ABL. Leukemia 2001;15(4):575-582.

(65) Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: The control of NF-κB activity. Annu Rev Immunol 2000;18:621-663.

(66) Lavon I, Goldberg I, Amit S, Landsman L, Jung S, Tsuberi B-, et al. High susceptibility to bacterial infection, but no liver dysfunction, in mice compromised for hepatocyte NF-κB activation. Nat Med 2000;6(5):573-577.

(67) Asimakopoulos FA, Shteper PJ, Krichevsky S, Fibach E, Polliack A, Rachmilewitz E, et al. ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia. Blood 1999;94(7):2452-2460.

(68) Asimakopoulos FA, Shteper PJ, Fibach E, Rachmilewitz E, Ben-Neriah Y, Ben-Yehuda D. Prognostic significance of c-ABL methylation in chronic myelogenous leukemia: Still an open question [4]. Blood 1999;94(3):1141.

(69) Sionov RV, Moallem E, Berger M, Kazaz A, Gerlitz O, Ben-Neriah Y, et al. c-Abl neutralizes the inhibitory effect of Mdm2 on p53. J Biol Chem 1999;274(13):8371-8374.

(70) Yaron A, Hatzubai A, Davis M, Lavon I, Amit S, Manning AM, et al. Identification of the receptor component of the IκBα-ubiquitin ligase. Nature 1998;396(6711):590-594.

(71) Avraham A, Jung S, Samuels Y, Seger R, Ben-Neriah Y. Co-stimulation-dependent activation of a JNK-kinase in T lymphocytes. Eur J Immunol 1998;28(8):2320-2330.

(72) Yedidia Y, Ben-Neriah Y, Jung S. Primary B cells essentially lack constitutive NF-κB activity. Eur J Immunol 1998;28(1):30-36.

(73) Ben-Yehuda D, Krichevsky S, Rachmilewitz EA, Avraham A, Palumbo GA, Frassoni F, et al. Molecular follow-up of disease progression and interferon therapy in chronic myelocytic leukemia. Blood 1997;90(12):4918-4923.

(74) Yaron A, Gonen H, Alkalay I, Hatzubai A, Jung S, Beyth S, et al. Inhibition of NF-κB cellular function via specific targeting of the IκB-ubiquitin ligase. EMBO J 1997;16(21):6486-6494.

(75) Alkalay I, Yaron A, Hatzubai A, Orian A, Ciechanover A, Ben-Neriah Y. Stimulation-dependent IκBα phosphorylation marks the NF-κb inhibitor for degradation via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 1995;92(23):10599-10603.

(76) JUNG S, YARON A, ALKALAY I, HATZUBAI A, AVRAHAM A, BEN‐NERIAH Y. Costimulation Requirement for AP‐1 and NF‐κB Transcription Factor Activation in T Cells. Ann New York Acad Sci 1995;766(1):245-252.

(77) Ciechanover A, Laszlo A, Bercovich B, Stancovski I, Alkalay I, Ben-Neriah Y, et al. The ubiquitin-mediated proteolytic system: Involvement of molecular chaperones, degradation of oncoproteins, and activation of transcriptional regulators. COLD SPRING HARBOR SYMP QUANT BIOL 1995;60:491-501.

(78) Ben-Neriah Y, Alkalay I, Yaron A, Hatzubai A, Jung S. Signalling intermediates of CD28. Res Immunol 1995;146(3):154-158.

(79) Alkalay I, Yaron A, Hatzubai A, Jung S, Avraham A, Gerlitz O, et al. In vivo stimulation of IκB phosphorylation is not sufficient to activate NF-κB. Mol Cell Biol 1995;15(3):1294-1301.

(80) Zion M, Ben-Yehuda D, Avraham A, Cohen O, Wetzler M, Melloul D, et al. Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia. Proc Natl Acad Sci U S A 1994;91(22):10722-10726.

(81) Su B, Jacinto E, Hibi M, Kallunki T, Karin M, Ben-Neriah Y. JNK is involved in signal integration during costimulation of T lymphocytes. Cell 1994;77(5):727-736.

(82) Levitzki A, Gazit A, Anafi M, Ben-Neriah Y. Tyrphostins as potential antileukemic agents. Leukemia 1993;7(9):1481.

(83) Anafi M, Gazit A, Zehavi A, Ben-Neriah Y, Levitzki A. Tyrphostin-induced inhibition of p210(bcr-abl) tyrosine kinase activity induces K562 to differentiate. Blood 1993;82(12):3524-3529.

(84) Henkel T, Machleidt T, Alkalay I, Krönke M, Ben-Neriah Y, Baeuerle PA. Rapid proteolysis of IκB-α is necessary for activation of transcription factor NF-κB. Nature 1993;365(6442):182-185.

(85) Melloul D, Ben-Neriah Y, Cerasi E. Glucose modulates the binding of an islet-specific factor to a conserved sequence within the rat I and the human insulin promoters. Proc Natl Acad Sci U S A 1993;90(9):3865-3869.

(86) Dikstein R, Heffetz D, Ben-Neriah Y, Shaul Y. c-abl has a sequence-specific enhancer binding activity. Cell 1992;69(5):751-757.

(87) Anafi M, Gazit A, Gilon C, Ben-Neriah Y, Levitzki A. Selective interactions of transforming and normal abl proteins with ATP, tyrosine-copolymer substrates, and tyrphostins. J Biol Chem 1992;267(7):4518-4523.

(88) Bauskin AR, Alkalay I, Ben-Neriah Y. Redox regulation of a protein tyrosine kinase in the endoplasmic reticulum. Cell 1991;66(4):685-696.

(89) Nefesh I, Bauskin AR, Alkalay I, Golembo M, Ben-neriah Y. IL-3 facilitates lymphocyte hexose transport by enhancing the intrinsic activity of the transport system. Int Immunol 1991;3(8):827-831.

(90) Wertheimer E, Sasson S, Cerasi E, Ben-Neriah Y. The ubiquitous glucose transporter GLUT-1 belongs to the glucose-regulated protein family of stress-inducible proteins. Proc Natl Acad Sci U S A 1991;88(6):2525-2529.

(91) Daley GQ, Ben-Neriah Y. Implicating the bcr/abl gene in the pathogenesis of philadelphia chromosome-positive human leukemia. Adv Cancer Res 1991;57(C):151-184.

(92) Siracusa LD, Silan CM, Justice MJ, Mercer JA, Bauskin AR, Ben-Neriah Y, et al. A molecular genetic linkage map of mouse chromosome 2. Genomics 1990;6(3):491-504.

(93) Bauskin AR, Zion M, Szpirer J, Szpirer C, Islam MQ, Levan G, et al. Expression and chromosomal assignment of a novel protein-tyrosine kinase gene related to the insulin receptor family. Haematol Blood Transfus 1989;32:453-460.

(94) Ben-Neriah Y, Bauskin AR. Leukocytes express a novel gene encoding a putative transmembrane protein-kinase devoid of an extracellular domain. Nature 1988;333(6174):672-676.

(95) Clark SS, Mclaughlin J, Timmons M, Pendergast AM, Ben-Neriah Y, Dow LW, et al. Expression of a distinctive BCR-ABL oncogene in Ph1-positive Acute Lymphocytic Leukemia (ALL). Science 1988;239(4841):775-777.

(96) Thomas ML, Reynolds PJ, Chain A, Ben-Neriah Y, Trowbridge IS. B-cell variant of mouse T200 (Ly-5): evidence for alternative mRNA splicing. Proc Natl Acad Sci U S A 1987;84(15):5360-5363.

(97) Ben-Neriah Y, Bernards A, Paskind M, Daley GQ, Baltimore D. Alternative 5′ exons in c-abl mRNA. Cell 1986;44(4):577-586.

(98) Ben-Neriah Y, Baltimore D. Structural modification of c-abl in lymphoma and leukemia. Curr Top Microbiol Immunol 1986;132:81-89.

(99) Ben-Neriah Y, Daley GQ, Mes-Masson A-, Witte ON, Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 1986;233(4760):212-214.

(100) Eshhar Z, Gigi O, Givol D, Ben‐Neriah Y. Monoclonal anti‐VH antibodies recognize a common VH determinant expressed on immunoglobulin heavy chains from various species. Eur J Immunol 1983;13(7):533-540.

(101) Rechavi G, Bienz B, Ram D, Ben-Neriah Y, Cohen JB, Zakut R, et al. Organization and evolution of immunoglobulin V(H) gene subgroups. Proc Natl Acad Sci U S A 1982;79(14 I):4405-4409.

(102) Cohen JB, Effron K, Rechavi G, Ben-Neriah Y, Zakut R, Givol D. Simple DNA sequences in homologous flanking regions near immunoglobulin VH genes: A role in gene interaction? Nucleic Acids Res 1982;10(11):3353-3370.

(103) Lonai P, Puri J, Bitton S, Ben-Neriah Y, Givol D, Hämmerling GJ. H-2-restricted helper factor secreted by cloned hybridoma cells. J Exp Med 1981;154(3):942-951.

(104) Ben‐Neriah Y, Cohen JB, Rechavi G, Zakut R, Givol D. Polymorphism of germ‐line immunoglobulin VH genes correlates with allotype and idiotype markers. Eur J Immunol 1981;11(12):1017-1020.

(105) Eshhar Z, Apte RN, Löwy I, Ben-neriah Y, Givol D, Mozes E. T-cell hybridoma bearing heavy chain variable region determinants producing (T,G)-A--L-specific helper factor. Nature 1980;286(5770):270-272.

(106) Elliott BE, Nagy ZA, Takacs BJ, Ben-Neriah Y, Givol D. Antigen-binding receptors on T cells from long-term MLR. Evidence of binding sites for allogeneic and self-MHC products. Immunogenetics 1980;11(1):177-190.

(107) Elliott BE, Nagy ZA, Ben-Neriah Y, Givol D. Alloactivated Lyt 1 +2- T lymphoblasts bind syngeneic Ia antigens. Nature 1980;285(5765):496-498.

(108) Eichmann K, Ben‐Neriah Y, Hetzelberger D, Polke C, Givol D, Lonai P. Correlated expression of VH framework and VHidiotypic determinants on T helper cells and on functionally undefined T cells binding group A streptococcal carbohydrate. Eur J Immunol 1980;10(2):105-112.

(109) Puri J, Ben‐Neriah Y, Givol D, Lonai P. Antibodies to immunoglobulin heavy chain variable regions protect helper cells from specific suicide by radiolabeled antigen. Eur J Immunol 1980;10(4):281-284.

(110) Ben-Neriah Y, Lonai P, Givol D. Preparation and characterization of anti-framework antibodies to the κ-chain variable region (V(κ)) of mouse immunoglobulins. J Immunol 1980;124(2):691-695.

(111) Cramer M, Krawinkel U, Melchers I, Imanishi‐Kari T, Rajewsky K, Ben‐Neriah Y, et al. Isolated hapten‐binding receptors of sensitized lymphocytes. IV. Expression of immimoglobulin variable regions in (4‐hydroxy‐3‐nitrophenyl) acetyl (NP)‐specific receptors isolated from murine B and T lymphocytes. Eur J Immunol 1979;9(4):332-338.

(112) Ben‐Neriah Y, Givol D, Gavish M. Anti‐V region framework antibodies affect the ligand binding of VL dimer. Eur J Immunol 1979;9(1):91-93.

(113) Gavish M, Ben Neriah Y, R. Z, D. G, R.A. D, Jackson WRC. On the role of Tyr 34L in the antibody combining site of the dinitrophenyl binding protein 315. Mol Immunol 1979;16(11):957-963.

(114) Givol D, Gavish M, Zakut R, Ben-Neriah Y, Lonai P. Combining site and antigenic determinants of the V regions. Haematologia 1978;12(1-4):15-24.

(115) Ben‐Neriah Y, Lonai P, Gavish M, Givol D. Preparation and characterization of antibodies to the λ chain variable region (Vλ) of mouse immunoglobulins. Eur J Immunol 1978;8(11):792-796.

(116) Lonai P, Ben‐Neriah Y, Steinman L, Givol D. Selective participation of immunoglobulin V region and major histocompatibility complex products in antigen binding by T cells. Eur J Immunol 1978;8(12):827-832.

(117) Ben‐Neriah Y, Wuilmart C, Lonai P, Givol D. Preparation and characterization of anti‐framework antibodies to the heavy chain variable region (VH) of mouse immunoglobulins. Eur J Immunol 1978;8(11):797-801.